Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
4(57%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
1
14%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated4
Completed3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
42.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

terminated457%
completed343%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus

NCT01222078
terminatedphase_2

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

NCT01114503
completedphase_1

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

NCT02000817
terminatedphase_2

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321
completedphase_3

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

NCT01123083
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01222078Phase 2

Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus

Terminated
NCT01114503Phase 2

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

Terminated
NCT02000817Phase 1

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Completed
NCT00451321Phase 2

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Terminated
NCT01123083Phase 3

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Completed
NCT01077531Phase 1

Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis

Terminated
NCT00946257Phase 1

Subcutaneous Administration of Otelixizumab to T1DM Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7